Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics is expected to achieve significant milestones and data in its ongoing clinical trials, which could serve as strong catalysts for the company's stock. With no revenue, the company's main product candidate, (Z)-endoxifen, is being evaluated for the treatment and prevention of breast cancer and other indications, with plans to enter the metastatic breast cancer market. Despite risks such as liquidity and regulatory approvals, Ascendiant Capital Markets has maintained a BUY rating for the company with a target price of $8.00, based on its strong growth prospects and significant upside potential.

Bears say

Atossa Therapeutics is making steady progress on its clinical trials and is actively cooperating with the FDA to explore additional indications for its lead product candidate, (Z)-endoxifen. However, the company's drugs are still in the early stages of development, making them highly risky investments. Despite the potential billion dollar market for Atossa's products, the potential for clinical trial failures remains a significant concern, making a negative outlook on the stock justifiable.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.